Article Text

MG-112 Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A
  1. Lucas Bronicki1,
  2. Claire Redin1,
  3. Severine Drunat1,
  4. Amélie Piton1,
  5. Michael Lyons1,
  6. Sandrine Passemard1,
  7. Clarisse Baumann1,
  8. Laurence Faivre1,
  9. Julien Thevenon1,
  10. Jean-Baptiste Rivière1,
  11. Bertrand Isidor1,
  12. Grace Gan1,
  13. Christine Francannet1,
  14. Murat Gunel1,
  15. Julie Jones1,
  16. Joseph Gleeson1,
  17. Marjolaine Willems1,
  18. Jean-Louis Mandel1,
  19. Roger E Stevenson1,
  20. Michael Friez1,
  21. Arthur S Aylsworth2
  1. 1Greenwood Genetic Center
  2. 2University of North Carolina at Chapel Hill


Background The dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) gene on chromosome 21q22.13 within the Down syndrome critical region has been implicated in syndromic intellectual disability associated with Down syndrome and autism. DYRK1A plays a critical role in brain growth and development primarily by regulating cell proliferation, neurogenesis, neuronal plasticity and survival. Several patients with chromosome 21 aberrations, such as partial monosomy, involving multiple genes including DYRK1A have been reported. In addition, seven other individuals have been described with chromosomal rearrangements, intragenic deletions or truncating mutations that specifically disrupt DYRK1A. Most of these patients have microcephaly and all have significant intellectual disability.

Objectives The purpose of this study was to further delineate the recurrent clinical features and types of mutations that disrupt DYRK1A in patients with ‘DYRK1A syndrome’.

Design/method Targeted or whole exome next-generation sequencing and array comparative genomic hybridization analysis were used to identify DNA sequence variations and copy number variants, respectively.

Results We identified unique mutations in DYRK1A in nine patients and a large chromosomal deletion that encompassed DYRK1A in one patient. These individuals had a recurrent pattern of clinical manifestations including primary or acquired microcephaly, intellectual disability ranging from mild to severe,  speech delay or absence, seizures, autism, motor delay, deep-set eyes, poor feeding and poor weight gain.

Conclusions Based on the increasing identification of mutations in DYRK1A, we suggest this gene be considered as potentially causative in patients presenting with intellectual disability, primary or acquired microcephaly, feeding problems and absent or delayed speech with or without seizures.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.